The top priority of CEO is to protect and grow the
Post# of 30067
Posted On: 10/12/2014 1:04:07 PM
The top priority of CEO is to protect and grow the business, not to protect shareholders. The shareholders will benefit as the business grows.
This priority is especially important for small biotechs like AMBS. Small biotechs need to survive against big and ruthless sharks, be it hedge funds, BP or even certain authorities. Only when one day AMBS becomes a sizeable pharma, then AMBS can afford to look into more specific measures solely for shareholders.
Contrary to what most feel, I thought Gerald should not reveal too many of his cards to the public like us unless they are complementary to his strategies against the sharks as a leverage.
There are 1001 possibilities why AMBS share price is what it is today. Some of them could be:
1. Some BP throwing a few millions of dollars in the market to depress AMBS price to force AMBS to accept a cut-throat partnership deal that can save BP say $500m
2. Some hegde fund or financial institution are aware that AMBS is eager to uplist and want to force AMBS hands to undertake certain desperate financial measures
3. Some "informed" parties pacing the collection of cheap shares knowing well the progress including deal negotiation
Investment as a public shareholder is never 100% transparent. And like it or not, a big dose of faith is required especially for small biotechs like AMBS.
I would prefer Gerald to be pro-business than to be pro-shareholder at this stage. This is fine with me as a long-term shareholder.
This priority is especially important for small biotechs like AMBS. Small biotechs need to survive against big and ruthless sharks, be it hedge funds, BP or even certain authorities. Only when one day AMBS becomes a sizeable pharma, then AMBS can afford to look into more specific measures solely for shareholders.
Contrary to what most feel, I thought Gerald should not reveal too many of his cards to the public like us unless they are complementary to his strategies against the sharks as a leverage.
There are 1001 possibilities why AMBS share price is what it is today. Some of them could be:
1. Some BP throwing a few millions of dollars in the market to depress AMBS price to force AMBS to accept a cut-throat partnership deal that can save BP say $500m
2. Some hegde fund or financial institution are aware that AMBS is eager to uplist and want to force AMBS hands to undertake certain desperate financial measures
3. Some "informed" parties pacing the collection of cheap shares knowing well the progress including deal negotiation
Investment as a public shareholder is never 100% transparent. And like it or not, a big dose of faith is required especially for small biotechs like AMBS.
I would prefer Gerald to be pro-business than to be pro-shareholder at this stage. This is fine with me as a long-term shareholder.
(0)
(0)